Corcept Therapeutics INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Daniel N Swisher Jr, a Director of Corcept Therapeutics Inc, sold 1,500 shares of common stock on November 10, 2026 for $74.07 per share.
NASDAQ
Sean Maduck, See Remarks of Corcept Therapeutics Inc, sold 25,000 shares of common stock on November 2, 2026.
NASDAQ
Roberto Wandenkolk Vieira, President, Oncology of Corcept Therapeutics Inc, sold 8,333 shares of common stock on November 2, 2026.
NASDAQ
James N Wilson, a Director of Corcept Therapeutics Inc, sold 10,000 shares of common stock on October 15, 2026.
NASDAQ
Roberto Wandenkolk Vieira, President, Oncology of Corcept Therapeutics Inc, sold 8,333 shares of common stock on October 2, 2026.
NASDAQ
Joseph Douglas Lyon, See Remarks of Corcept Therapeutics Inc, sold 10,000 shares of common stock on October 1, 2026.
NASDAQ
Sean Maduck, See Remarks of Corcept Therapeutics Inc, sold 25,000 shares of common stock on October 1, 2026.
NASDAQ
Justin Frederick Gunn, See Remarks of Corcept Therapeutics Inc, received 100,000 shares of common stock on October 1, 2026.
NASDAQ
Roberto Wandenkolk Vieira, President, Oncology of Corcept Therapeutics Inc, sold 296 shares of common stock on September 16, 2026 for $100.82 per share.
NASDAQ
Gary Charles Robb, Chief Business Officer of Corcept Therapeutics Inc, reported multiple transactions in common stock on September 17, 2026.
NASDAQ
Joseph Douglas Lyon, See Remarks of Corcept Therapeutics Inc, sold 10,000 shares of common stock on September 14, 2026.
NASDAQ
James N Wilson, a Director of Corcept Therapeutics Inc, sold 10,000 shares of common stock on September 15, 2026.
NASDAQ
William Guyer, Chief Development Officer of Corcept Therapeutics Inc, reported multiple transactions in common stock on September 1, 2026.
NASDAQ
Sean Maduck, See Remarks of Corcept Therapeutics Inc, sold 25,000 shares of common stock on September 1, 2026.
NASDAQ
Atabak Mokari, Chief Financial Officer of Corcept Therapeutics Inc, reported multiple transactions in common stock on September 1, 2026.
NASDAQ
Gary Charles Robb, Chief Business Officer of Corcept Therapeutics Inc, reported multiple transactions in common stock on September 1, 2026.
NASDAQ
Roberto Wandenkolk Vieira, President, Oncology of Corcept Therapeutics Inc, sold 58,333 shares of common stock on September 1, 2026.
NASDAQ
Joseph Douglas Lyon, See Remarks of Corcept Therapeutics Inc, reported multiple transactions in common stock on September 1, 2026.
NASDAQ
David L Mahoney, a Director of Corcept Therapeutics Inc, sold 103,606 shares of common stock on August 18, 2026.
NASDAQ
Sean Maduck, See Remarks of Corcept Therapeutics Inc, sold 3,664 shares of common stock on August 14, 2026 for $114.49 per share.
NASDAQ
James N Wilson, a Director of Corcept Therapeutics Inc, sold 10,000 shares of common stock on August 14, 2026.
NASDAQ
Gary Charles Robb, Chief Business Officer of Corcept Therapeutics Inc, sold 10,000 shares of common stock on August 17, 2026 for $116.26 per share.
NASDAQ
Sean Maduck, See Remarks of Corcept Therapeutics Inc, sold 1,031 shares of common stock on August 10, 2026 for $114.52 per share.
NASDAQ
William Guyer, Chief Development Officer of Corcept Therapeutics Inc, sold 16,300 shares of common stock on August 10, 2026.
NASDAQ
William Guyer, Chief Development Officer of Corcept Therapeutics Inc, sold 3,700 shares of common stock on August 4, 2026 for $113.12 per share.
NASDAQ
Sean Maduck, See Remarks of Corcept Therapeutics Inc, sold 20,305 shares of common stock on August 3, 2026 for $114.70 per share.
NASDAQ
Joseph Douglas Lyon, See Remarks of Corcept Therapeutics Inc, sold 1,540 shares of common stock on August 3, 2026 for $114.16 per share.
NASDAQ
Atabak Mokari, Chief Financial Officer of Corcept Therapeutics Inc, sold 80,000 shares of common stock on July 30, 2026.
NASDAQ
James N Wilson, a Director of Corcept Therapeutics Inc, sold 10,000 shares of common stock on July 15, 2026.
NASDAQ
Atabak Mokari, Chief Financial Officer of Corcept Therapeutics Inc, sold 40,000 shares of common stock on July 15, 2026.